Security Holdings. The shares of Preferred Stock held by each Investor, as applicable, as of the date hereof are correctly described on Schedule B attached hereto. The Investor does not hold any other securities or equity interests in the Company other than what is set forth opposite such Investor’s name on Schedule B attached hereto, Schedule B to the Note Conversion Agreement, dated January 8, 2016 and Schedule B to the Warrant Exercise Agreement, dated January 8, 2016, each of which is incorporated herein by reference as though fully set forth herein and made a part of this Agreement.
Appears in 1 contract
Sources: Preferred Stock Exchange Agreement (Oxis International Inc)
Security Holdings. The shares of Preferred Stock held by each Investor, as applicable, as of the date hereof are correctly described on Schedule B attached hereto. The Investor does not hold any other securities or equity interests in the Company other than what is set forth opposite such Investor’s 's name on Schedule B attached hereto, Schedule B to the Note Conversion Agreement, dated January 8, 2016 and Schedule B to the Warrant Exercise Agreement, dated January 8, 2016, each of which is incorporated herein by reference as though fully set forth herein and made a part of this Agreement.
Appears in 1 contract
Sources: Preferred Stock Exchange Agreement (Oxis International Inc)
Security Holdings. The shares of Preferred Stock held by each Investor, as applicable, as of the date hereof are correctly described on Schedule B attached hereto. The Investor does not hold any other securities or equity interests in the Company other than what is set forth opposite such Investor’s name on Schedule B attached hereto, Schedule B to the Note Conversion Agreement, dated January 8August 25, 2016 2017, and Schedule B to the Warrant Exercise Agreement, dated January 8August 25, 20162017, each of which is incorporated herein by reference as though fully set forth herein and made a part of this Agreement.
Appears in 1 contract
Sources: Preferred Stock Exchange Agreement (GT Biopharma, Inc.)